Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open Label, Multi-Center, Extension Study to Assess Antibody Persistence and Response to a Third or Fifth Dose of Novartis Meningococcal B Recombinant Vaccine in 4-Year-Old Children Who Previously Participated in Study V72P12E1

NCT01717638 is registered in ClinicalTrials.gov with Novartis Vaccines as lead sponsor.

NCT NCT01717638
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01717638 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open Label, Multi-Center, Extension Study to Assess Antibody Persistence and Response to a Third or Fifth Dose of Novartis Meningococcal B Recombinant Vaccine in 4-Year-Old Children Who Previously Participated in Study V72P12E1
Lead sponsor
Novartis Vaccines
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2012
Completion date
October 31, 2013
Enrollment
805 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

meningococcal disease, meningococcal meningitis